FDA granted Priority Review to MCNA, developed by Telesta, for the treatment of high-risk, non-muscle invasive bladder cancer patients who are refractory or relapsing from BCG front-line treatment.
For a year before an osteosarcoma was found in her right proximal tibia, Sammy Ulloa, pushing through pain, persisted with her training as a Division I track and field and cross-country competitor.
